초록 ▼

A pump assembly 1, 33, 200 adapted for continuous flow pumping of blood. In a particular form the pump 1, 200 is a centrifugal pump wherein the impeller 100, 204 is entirely sealed within the pump housing 2, 201 and is exclusively hydrodynamically suspended therein as the impeller rotates within the

A pump assembly 1, 33, 200 adapted for continuous flow pumping of blood. In a particular form the pump 1, 200 is a centrifugal pump wherein the impeller 100, 204 is entirely sealed within the pump housing 2, 201 and is exclusively hydrodynamically suspended therein as the impeller rotates within the fluid 105 urged by electromagnetic means external to the pump cavity 106, 203. Hydrodynamic suspension is assisted by the impeller 100, 204 having deformities therein such as blades 8 with surfaces tapered from the leading edges 102, 223 to the trailing edges 103, 224 of bottom and top edges 221, 222 thereof.

대표청구항 ▼

A pump assembly 1, 33, 200 adapted for continuous flow pumping of blood. In a particular form the pump 1, 200 is a centrifugal pump wherein the impeller 100, 204 is entirely sealed within the pump housing 2, 201 and is exclusively hydrodynamically suspended therein as the impeller rotates within the

A pump assembly 1, 33, 200 adapted for continuous flow pumping of blood. In a particular form the pump 1, 200 is a centrifugal pump wherein the impeller 100, 204 is entirely sealed within the pump housing 2, 201 and is exclusively hydrodynamically suspended therein as the impeller rotates within the fluid 105 urged by electromagnetic means external to the pump cavity 106, 203. Hydrodynamic suspension is assisted by the impeller 100, 204 having deformities therein such as blades 8 with surfaces tapered from the leading edges 102, 223 to the trailing edges 103, 224 of bottom and top edges 221, 222 thereof. of claim 1. 17. A sprayable composition according to claim 16 wherein the sprayable composition is an aerosol. 18. A sprayable composition according to claim 17 wherein the sprayable composition is a cosmetic material. 19. The composition of claim 17 wherein the material to be sprayed is a medicinal material. 20. A process for removing 2-methylbutane from 1,1,1,2-tetrafluoroethane which process comprises distilling a mixture of 1,1,1,2-tetrafluoroethane, HFC-245fa and 2-methylbutane to separate an azeotrope or azeotrope-like composition consisting essentially of 1,1,1,2-tetrafluoroethane, HFC-245fa, and 2-methylbutane from 1,1,1,2-tetrafluoroethane present in excess of the concentration of said azeotrope. 21. A process as described in claim 20 wherein said mixture of 1,1,1,2-tetrafluoroethane and 2-methylbutane is phase separated to remove bulk amounts of 2-methylbutane before conducting said distillation step. 22. A closed cell foam containing a cell gas prepared from a blowing agent as defined in claim 4. 23. A closed cell foam containing a cell gas prepared from a blowing agent as defined in claim 5. 24. A closed cell foam containing a cell gas prepared from a blowing agent as defined in claim 6. nd 0.1 to 10 wt. %, based on the non-volatile content of the coating composition, of an additive which is a polyamide. 2. The composition of claim 1, wherein said polyamide is selected form the group consisting of waxy polyamide polymers, fatty acid-modified polyamides, oligomeric fatty acid amides and polymeric fatty acid amides. 3. The composition of claim 2, wherein said component is a mixture of an amine-modified polyether acrylate having a dynamic viscosity of about 800 mPa.s and tripropylene glycol diacrylate and wherein said polyamide is a polyamide wax. 4. The composition of claim 2, wherein said component is a mixture of an amine-modified polyether acrylate having a dynamic viscosity of about 800 mPa·s and dipropylene glycol diacrylate and wherein said polyamide is a polyamide wax. he non-steroidal anti-inflammatory and analgesic agent is ketoprofen, indomethacin, bufexamac, ibuprofen or piroxicam.